GE Healthcare's Alzheimer's Imaging Agent Vizamyl Snags FDA Approval

GE Healthcare announced the FDA approval of Vizamyl, a radioactive diagnostic agent indicated for Positron Emission Tomography imaging of the brain to estimate beta amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease.
DeviceSpace